ES2317827T3 - Metodo cronomatografico de purificacion de albumina. - Google Patents
Metodo cronomatografico de purificacion de albumina. Download PDFInfo
- Publication number
- ES2317827T3 ES2317827T3 ES00901252T ES00901252T ES2317827T3 ES 2317827 T3 ES2317827 T3 ES 2317827T3 ES 00901252 T ES00901252 T ES 00901252T ES 00901252 T ES00901252 T ES 00901252T ES 2317827 T3 ES2317827 T3 ES 2317827T3
- Authority
- ES
- Spain
- Prior art keywords
- albumin
- phase
- exchange
- chromatography
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 115
- 238000000746 purification Methods 0.000 title claims description 48
- 102000009027 Albumins Human genes 0.000 claims abstract description 347
- 108010088751 Albumins Proteins 0.000 claims abstract description 346
- 230000008569 process Effects 0.000 claims abstract description 84
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 77
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims abstract description 33
- 108091026890 Coding region Proteins 0.000 claims abstract description 21
- 239000001963 growth medium Substances 0.000 claims abstract description 21
- 230000002538 fungal effect Effects 0.000 claims abstract description 20
- 230000002829 reductive effect Effects 0.000 claims abstract description 19
- 108020004705 Codon Proteins 0.000 claims abstract description 13
- 238000013519 translation Methods 0.000 claims abstract description 12
- 238000012239 gene modification Methods 0.000 claims abstract description 11
- 230000005017 genetic modification Effects 0.000 claims abstract description 11
- 235000013617 genetically modified food Nutrition 0.000 claims abstract description 11
- 229910052759 nickel Inorganic materials 0.000 claims abstract description 11
- 238000005621 mannosylation reaction Methods 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 94
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 239000000872 buffer Substances 0.000 claims description 60
- 238000004587 chromatography analysis Methods 0.000 claims description 58
- 239000011159 matrix material Substances 0.000 claims description 50
- 238000011026 diafiltration Methods 0.000 claims description 43
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 36
- 230000004151 fermentation Effects 0.000 claims description 36
- 238000000855 fermentation Methods 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 238000005349 anion exchange Methods 0.000 claims description 34
- 238000005341 cation exchange Methods 0.000 claims description 33
- 125000002091 cationic group Chemical group 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 25
- 125000000129 anionic group Chemical group 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 24
- 238000005277 cation exchange chromatography Methods 0.000 claims description 22
- 239000002609 medium Substances 0.000 claims description 22
- 241000235648 Pichia Species 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 18
- 238000001042 affinity chromatography Methods 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 238000005571 anion exchange chromatography Methods 0.000 claims description 16
- 150000001768 cations Chemical class 0.000 claims description 16
- 229910001453 nickel ion Inorganic materials 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 238000010790 dilution Methods 0.000 claims description 15
- 239000012895 dilution Substances 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 15
- 238000010979 pH adjustment Methods 0.000 claims description 15
- -1 sulfopropyl substituents Chemical group 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 239000003638 chemical reducing agent Substances 0.000 claims description 14
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 230000003750 conditioning effect Effects 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 241000233866 Fungi Species 0.000 claims description 11
- 238000007792 addition Methods 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 235000011148 calcium chloride Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000005562 fading Methods 0.000 claims description 7
- 241000235070 Saccharomyces Species 0.000 claims description 6
- 150000001450 anions Chemical class 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- ILOJFJBXXANEQW-UHFFFAOYSA-N aminooxy(phenyl)borinic acid Chemical compound NOB(O)C1=CC=CC=C1 ILOJFJBXXANEQW-UHFFFAOYSA-N 0.000 claims description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 241000235649 Kluyveromyces Species 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 238000004362 fungal culture Methods 0.000 claims description 2
- 230000000869 mutational effect Effects 0.000 claims description 2
- 101001123538 Nicotiana tabacum Putrescine N-methyltransferase 1 Proteins 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 12
- 238000011210 chromatographic step Methods 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 167
- 210000004027 cell Anatomy 0.000 description 42
- 102000008100 Human Serum Albumin Human genes 0.000 description 36
- 108091006905 Human Serum Albumin Proteins 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 34
- 239000000047 product Substances 0.000 description 25
- 238000000108 ultra-filtration Methods 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 23
- 108010062580 Concanavalin A Proteins 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 101150053681 pmt gene Proteins 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 101100241858 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OAC1 gene Proteins 0.000 description 12
- 229920002684 Sepharose Polymers 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 101150092906 pmt1 gene Proteins 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- 101100408676 Caenorhabditis elegans pmt-1 gene Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000235058 Komagataella pastoris Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000000717 retained effect Effects 0.000 description 9
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 8
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- DIRRKLFMHQUJCM-UHFFFAOYSA-N (2-aminophenyl)boronic acid Chemical compound NC1=CC=CC=C1B(O)O DIRRKLFMHQUJCM-UHFFFAOYSA-N 0.000 description 6
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 6
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 6
- 241001138401 Kluyveromyces lactis Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 5
- 101100244390 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PMT7 gene Proteins 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003245 coal Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101150029408 PMT5 gene Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 101100043108 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spb1 gene Proteins 0.000 description 4
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000036252 glycation Effects 0.000 description 4
- 150000002402 hexoses Chemical class 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- ZHTJVFJXNTXXOV-UHFFFAOYSA-N 1-(5-acetyl-2,6-dimethyl-1,2-dihydropyridin-3-yl)ethanone Chemical compound CC1NC(C)=C(C(C)=O)C=C1C(C)=O ZHTJVFJXNTXXOV-UHFFFAOYSA-N 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 230000004989 O-glycosylation Effects 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 101150036326 PMT2 gene Proteins 0.000 description 3
- 108010031271 Saccharomyces cerevisiae Proteins Proteins 0.000 description 3
- 241000776233 Tisis Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000004061 bleaching Methods 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000006174 pH buffer Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000017105 transposition Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- NDVRKEKNSBMTAX-MVNLRXSJSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O NDVRKEKNSBMTAX-MVNLRXSJSA-N 0.000 description 2
- GDTSJMKGXGJFGQ-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound O1B([O-])OB2OB([O-])OB1O2 GDTSJMKGXGJFGQ-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101150007280 LEU2 gene Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 108010087568 Mannosyltransferases Proteins 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 101150014136 SUC2 gene Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 108091005996 glycated proteins Proteins 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 229940079710 sodium acetyltryptophanate Drugs 0.000 description 2
- UQSHZBSQKMVQBS-UHFFFAOYSA-M sodium;2-acetamido-3-(1h-indol-3-yl)propanoate Chemical compound [Na+].C1=CC=C2C(CC(NC(=O)C)C([O-])=O)=CNC2=C1 UQSHZBSQKMVQBS-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RTLULCVBFCRQKI-UHFFFAOYSA-N 1-amino-4-[3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=1)=CC=C(S(O)(=O)=O)C=1NC1=NC(Cl)=NC(Cl)=N1 RTLULCVBFCRQKI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 101100244387 Candida albicans (strain SC5314 / ATCC MYA-2876) PMT6 gene Proteins 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150079981 HSP150 gene Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- 102000006722 Mannosyltransferases Human genes 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 101150024216 PMT3 gene Proteins 0.000 description 1
- 101150086142 PMT4 gene Proteins 0.000 description 1
- 101150076940 PMT6 gene Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100319895 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YAP3 gene Proteins 0.000 description 1
- 101100160515 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YPS1 gene Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003816 axenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011035 continuous diafiltration Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- FYSNRPHRLRVCSW-UHFFFAOYSA-N dodecasodium;tetraborate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-] FYSNRPHRLRVCSW-UHFFFAOYSA-N 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- DKTXXUNXVCHYDO-UHFFFAOYSA-N phenoxyborinic acid Chemical compound OBOC1=CC=CC=C1 DKTXXUNXVCHYDO-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- VZPXDCIISFTYOM-UHFFFAOYSA-K trisodium;1-amino-4-[4-[[4-chloro-6-(3-sulfonatoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfonatoanilino]-9,10-dioxoanthracene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S([O-])(=O)=O)C=C1NC(C=C1S([O-])(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S([O-])(=O)=O)=C1 VZPXDCIISFTYOM-UHFFFAOYSA-K 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Glass Compositions (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9902000 | 1999-01-30 | ||
GB9902000A GB9902000D0 (en) | 1999-01-30 | 1999-01-30 | Process |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2317827T3 true ES2317827T3 (es) | 2009-05-01 |
Family
ID=10846743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES00901252T Expired - Lifetime ES2317827T3 (es) | 1999-01-30 | 2000-01-31 | Metodo cronomatografico de purificacion de albumina. |
Country Status (16)
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
EP1276756A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
ITBO20010426A1 (it) * | 2001-07-06 | 2003-01-06 | Alfa Wassermann Spa | Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
GB0202633D0 (en) * | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
KR20040095217A (ko) | 2002-02-07 | 2004-11-12 | 델타 바이오테크놀로지 리미티드 | 알부민-융합 항-혈관신생 펩타이드 |
SE526227C2 (sv) * | 2002-05-15 | 2005-08-02 | North China Pharmaceutical Group | Metod för rening av rekombinant humant serumalbumin |
GB0217033D0 (en) | 2002-07-23 | 2002-08-28 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
GB0304576D0 (en) | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
ES2380022T3 (es) | 2003-12-03 | 2012-05-07 | Monika KRÖZ | Proteínas de fusión a interleucina-11 |
GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
GB0329722D0 (en) * | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
JP2008523829A (ja) * | 2004-12-22 | 2008-07-10 | ノボザイムス アクティーゼルスカブ | 血清アルブミンの組換え生成 |
EP1831375B1 (en) | 2004-12-23 | 2014-07-16 | Novozymes Biopharma DK A/S | Gene expression technique |
WO2007063129A2 (en) * | 2005-12-02 | 2007-06-07 | Novozymes A/S | Insolation of peptides , polypeptides and proteins |
JP2007284425A (ja) * | 2006-03-20 | 2007-11-01 | Nokodai Tlo Kk | タンパク質の精製方法 |
JP5670634B2 (ja) * | 2006-07-13 | 2015-02-18 | アッパートン リミティド | タンパク質性物質の粒子の製造方法 |
WO2008012629A2 (en) | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
JP5256199B2 (ja) | 2006-08-07 | 2013-08-07 | テヴァ バイオファーマシューティカルズ ユーエスエー,インコーポレーティッド | アルブミン−インスリン融合タンパク質 |
ES2527756T3 (es) | 2007-02-02 | 2015-01-29 | Globeimmune, Inc. | Procedimientos mejorados de producción de vacunas con base de levadura |
CN101835801B (zh) | 2007-08-08 | 2014-09-10 | 诺维信生物制药丹麦公司 | 转铁蛋白变体和偶联物 |
JP4452324B2 (ja) * | 2008-03-31 | 2010-04-21 | 積水メディカル株式会社 | 精製血清アルブミン及び免疫学的測定方法 |
CN101684459B (zh) * | 2008-09-22 | 2012-01-25 | 上海普天欣生物技术有限公司 | CehA突变体蛋白、基因、重组载体及其用途和制备方法 |
CN101747437B (zh) | 2008-12-10 | 2012-09-26 | 浙江日升昌药业有限公司 | 凋亡素-ec-sod羧基末端蛋白转导域融合蛋白 |
JP5936112B2 (ja) | 2009-02-11 | 2016-06-15 | アルブミディクス アクティーゼルスカブ | アルブミン変異体及び複合体 |
AU2010215959A1 (en) | 2009-02-20 | 2011-08-04 | Ventria Bioscience | Cell culture media containing combinations of proteins |
CA2756247C (en) | 2009-04-09 | 2015-05-26 | Cellca Gmbh | Method for improved single cell cloning |
DK2427486T3 (en) * | 2009-05-07 | 2015-05-26 | Novozymes Biopharma Dk As | A process for purifying albumin |
CN101691581B (zh) * | 2009-06-25 | 2012-10-03 | 南京农业大学 | 染色体无标记随机整合载体pUTTns及其应用 |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
CN101690801B (zh) | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
CN103025757A (zh) * | 2010-04-29 | 2013-04-03 | 巴克斯特国际有限公司 | 二价阳离子结合蛋白在阴离子交换树脂上的纯化方法 |
EP2635598A1 (en) | 2010-11-01 | 2013-09-11 | Novozymes Biopharma DK A/S | Albumin variants |
CN102127164B (zh) * | 2010-12-20 | 2013-01-30 | 武汉禾元生物科技有限公司 | 一种从水稻种子中提取重组人血清白蛋白的方法 |
CN102532254B (zh) | 2010-12-24 | 2015-06-24 | 武汉禾元生物科技股份有限公司 | 一种从水稻种子中分离纯化重组人血清白蛋白的方法 |
CA2830660A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
CA2838964C (en) * | 2011-07-05 | 2021-07-13 | Novozymes Biopharma Dk A/S | Albumin formulation and use |
EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
JP6073916B2 (ja) * | 2011-12-05 | 2017-02-01 | ファクター バイオサイエンス インコーポレイテッド | 細胞に形質移入するための方法および製品 |
DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
EP3330283A3 (en) | 2012-03-16 | 2018-07-11 | Albumedix A/S | Albumin variants |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP3501550A1 (en) * | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US10501513B2 (en) * | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
CN102952836A (zh) * | 2012-11-02 | 2013-03-06 | 浙江海正药业股份有限公司 | 重组人长效白介素1受体拮抗剂融合蛋白的纯化方法 |
EP2917233A1 (en) | 2012-11-08 | 2015-09-16 | Novozymes Biopharma DK A/S | Albumin variants |
CN103880947B (zh) | 2012-12-21 | 2016-01-13 | 武汉禾元生物科技股份有限公司 | 一种分离纯化高纯度重组人血清白蛋白的层析方法 |
JP6742729B2 (ja) * | 2013-03-06 | 2020-08-19 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 宿主細胞および使用方法 |
KR102111078B1 (ko) | 2013-07-04 | 2020-05-18 | 노파르티스 아게 | O-만노실트랜스퍼라제 결핍 사상균 세포 및 이의 이용 방법 |
CA2928700C (en) | 2013-11-01 | 2019-01-15 | University Of Oslo | Albumin variants and uses thereof |
TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
TWI709570B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析法及製法 |
US9938319B2 (en) * | 2014-04-23 | 2018-04-10 | Alexion Pharmaceuticals, Inc. | Egg white processing |
SG11201700446XA (en) | 2014-07-21 | 2017-02-27 | Glykos Finland Oy | Production of glycoproteins with mammalian-like n-glycans in filamentous fungi |
PL3240798T3 (pl) * | 2015-01-01 | 2020-11-02 | Shilpa Medicare Limited | Nowy sposób skutecznego oczyszczania ludzkiej albuminy surowicy krwi |
JP7199809B2 (ja) | 2015-02-13 | 2023-01-06 | ファクター バイオサイエンス インコーポレイテッド | 核酸製品及びその投与方法 |
CA2979397A1 (en) | 2015-03-12 | 2016-09-15 | Board Of Trustees Of Michigan State University | Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases |
WO2016207730A1 (en) | 2015-06-22 | 2016-12-29 | The University Of Oslo | Targeting of vaccine antigen to an intracellular compartment |
CN105037487B (zh) * | 2015-08-12 | 2017-03-22 | 山东泰邦生物制品有限公司 | 一种人血白蛋白的制备方法 |
WO2017029407A1 (en) | 2015-08-20 | 2017-02-23 | Albumedix A/S | Albumin variants and conjugates |
CA3005953A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix Ltd | Improved protein expression strains |
CA3033788A1 (en) | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
ES2761854T3 (es) | 2016-10-04 | 2020-05-21 | Albumedix Ltd | Usos de albúmina de suero recombinante obtenida a partir de levadura |
WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
CN110770251A (zh) * | 2017-04-20 | 2020-02-07 | 诺和诺德股份有限公司 | 纯化白蛋白融合蛋白的方法 |
EP3642343B1 (en) | 2017-06-20 | 2021-12-08 | Albumedix Ltd. | Improved protein expression strains |
KR20210021004A (ko) * | 2018-06-15 | 2021-02-24 | 후소 야쿠힝 고교 가부시끼가이샤 | 생식 보조 의료용 배지 |
EP3843869A1 (en) | 2018-08-31 | 2021-07-07 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
CN111229023B (zh) * | 2018-11-29 | 2022-01-28 | 内蒙古东盛硅藻土科技创新产业园有限公司 | 一种化学降解添加剂 |
CN109879958A (zh) * | 2019-03-08 | 2019-06-14 | 中国人民解放军军事科学院军事医学研究院 | 一种低糖基化血清白蛋白的制备方法 |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
US20210096128A1 (en) * | 2019-10-01 | 2021-04-01 | Repligen Corporation | Determination of protein concentration in a fluid |
CN112858682B (zh) * | 2019-11-27 | 2023-06-02 | 广东唯实生物技术有限公司 | 用于尿微量白蛋白的检测试纸条及其制备方法、检测试剂盒和检测方法 |
EP4069200A1 (en) | 2019-12-04 | 2022-10-12 | Albumedix Ltd | Methods and compositions produced thereby |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
CN112062833A (zh) * | 2020-10-09 | 2020-12-11 | 国药集团武汉血液制品有限公司 | 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法 |
JP2024501601A (ja) | 2020-12-08 | 2024-01-15 | 通化安睿特生物製薬股▲フェン▼有限公司 | 組換えタンパク質を精製する方法 |
CN112646045A (zh) * | 2021-01-06 | 2021-04-13 | 海默斯(重庆)医学生物技术有限公司 | 一种重组角蛋白分离纯化方法 |
CN114907469A (zh) * | 2021-02-08 | 2022-08-16 | 首都医科大学附属北京朝阳医院 | 一种人血清中白蛋白分离纯化方法 |
CN113735963A (zh) * | 2021-09-10 | 2021-12-03 | 山东健通生物科技有限公司 | 一种重组人血清白蛋白纯化过程去除色素的方法 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9019919D0 (en) | 1990-09-12 | 1990-10-24 | Delta Biotechnology Ltd | Purification of proteins |
US5625041A (en) * | 1990-09-12 | 1997-04-29 | Delta Biotechnology Limited | Purification of proteins |
US2433905A (en) * | 1943-11-01 | 1948-01-06 | Jr Walter L Hughes | Method for the crystallization of albumin and the preparation of protein products therefrom |
AT317418B (de) | 1972-06-16 | 1974-08-25 | Brigitte Panhofer | Verfahren zur Herstellung von intravenös beim Menschen anwendbarem Humanalbumin aus menschlichen Placenten |
FR2190437B1 (US07993877-20110809-P00003.png) * | 1972-07-05 | 1975-08-08 | Merieux Inst | |
CA1044537A (en) | 1973-05-09 | 1978-12-19 | Amf Incorporated | Filter medium and process |
DE2537123A1 (de) | 1975-08-20 | 1977-03-03 | New Zealand Inventions Dev | Verfahren zur herstellung von albumin |
SE405549B (sv) * | 1975-10-09 | 1978-12-18 | Pharmacia Fine Chemicals Ab | Forfarande for isolering av albumin ur plasmaprodukter genom kromatografisk fraktionering |
US4043997A (en) * | 1976-05-28 | 1977-08-23 | Cutter Laboratories, Inc. | Method for isolating albumin using insoluble supports coupled to a dye |
US4075197A (en) * | 1976-09-20 | 1978-02-21 | Monsanto Company | Serum albumin production |
US4269605A (en) | 1978-06-28 | 1981-05-26 | Amicon Corporation | Method and kit for separation of glycoproteins |
IN150740B (US07993877-20110809-P00003.png) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
US4228154A (en) * | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
US4222934A (en) * | 1979-04-12 | 1980-09-16 | American National Red Cross | Preparation of albumin using ethanol |
CA1149298A (en) | 1979-04-12 | 1983-07-05 | Eugene H. Wegner | Production of yeast cells at high cell densities |
GB2053926B (en) | 1979-07-20 | 1983-02-23 | Atkinson A | Albumin extraction by affinity chromatography |
US4350156A (en) * | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4491946A (en) | 1981-03-09 | 1985-01-01 | Gould Inc. | Multi-station token pass communication system |
US4562251A (en) | 1981-03-26 | 1985-12-31 | Amicon Corporation | Agarose derivatives of amino phenyl boronic acid |
IL66614A (en) | 1981-08-28 | 1985-09-29 | Genentech Inc | Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it |
US4391801A (en) * | 1981-10-29 | 1983-07-05 | Cutter Laboratories, Inc. | Plasma protein fraction substantially free of acetate ions |
FR2543448A1 (fr) * | 1983-04-01 | 1984-10-05 | Rhone Poulenc Spec Chim | Procede de fractionnement du plasma |
US4748120A (en) * | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
DE3344656A1 (de) | 1983-12-09 | 1985-06-13 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung einer serumproteinloesung |
CA1286622C (en) | 1986-04-28 | 1991-07-23 | Chokyun Rha | Method for clarifying and stabilizing cell culture media |
JPS62294621A (ja) | 1986-06-13 | 1987-12-22 | Green Cross Corp:The | アルブミンの回収方法 |
JPS6383100A (ja) | 1986-09-26 | 1988-04-13 | Green Cross Corp:The | ヒト尿中アルブミンの製造方法 |
ES2052712T3 (es) | 1987-04-09 | 1994-07-16 | Delta Biotechnology Ltd | Vector de levadura. |
US4833233A (en) | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
CA1293217C (en) | 1987-11-09 | 1991-12-17 | Sooyoung Stanford Lee | Controlled growth rate fermentation |
IL88326A (en) | 1987-11-18 | 1993-03-15 | Gist Brocades Nv | Purification of serum albumin |
GB2214508A (en) | 1988-01-27 | 1989-09-06 | Bayer Ag | Plasmid vector for the efficient expression of foreign genes fused with newly conceived transcriptional and translational signal sequences. |
JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法 |
US4990447A (en) * | 1988-06-24 | 1991-02-05 | Gist-Brocades Nv | Process for the purification of serum albumin |
DE68925893T2 (de) | 1988-07-23 | 1996-08-08 | Delta Biotechnology Ltd | Sekretorische leader-sequenzen |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
US5277818A (en) * | 1988-10-31 | 1994-01-11 | The Green Cross Corporation | Albumin preparation and process for preparing the same |
JP3554796B2 (ja) | 1988-10-31 | 2004-08-18 | 三菱ウェルファーマ株式会社 | アルブミン製剤及びその製造方法 |
US4891221A (en) | 1988-11-23 | 1990-01-02 | Edward Shanborm | Whole blood antiviral process and composition |
FR2648048B1 (fr) | 1989-06-08 | 1994-06-03 | Lille Transfusion Sanguine | Procede de preparation de solutions d'albumine purifiee |
GB8913586D0 (en) | 1989-06-13 | 1989-08-02 | Technicol Limited | A method of determining the glycosylated protein level of a sample and an apparatus for use in the method |
JPH0768137B2 (ja) | 1989-06-15 | 1995-07-26 | 株式会社ミドリ十字 | アルブミン製剤及びその製法 |
SE500110C2 (sv) * | 1989-06-27 | 1994-04-18 | Kabi Pharmacia Ab | Sätt att rena ett protein från därtill bundna flervärda metalljoner |
GB8927480D0 (en) | 1989-12-05 | 1990-02-07 | Delta Biotechnology Ltd | Mutant fungal strain detection and new promoter |
JPH0671434B2 (ja) | 1989-09-18 | 1994-09-14 | 株式会社ミドリ十字 | ヒト血清アルブミンの製造方法 |
US5250662A (en) * | 1989-10-05 | 1993-10-05 | Alpha Therapeutic Corporation | Albumin purification |
CA2022165C (en) | 1989-10-05 | 1999-11-23 | Chong E. Chang | Albumin purification |
JP3127232B2 (ja) | 1990-03-08 | 2001-01-22 | ウェルファイド株式会社 | 蛋白質製剤の製造法 |
EP0452753B1 (en) | 1990-04-19 | 2004-06-23 | Bayer Corporation | Method for preparing essentially monomeric normal serum albumin (human) |
SE9002212D0 (sv) | 1990-06-21 | 1990-06-21 | Hightech Receptor Ab | Igg binding protein |
JP3230091B2 (ja) | 1990-06-25 | 2001-11-19 | ウェルファイド株式会社 | ヒト血清アルブミンの着色抑制方法 |
JP2982296B2 (ja) | 1990-11-19 | 1999-11-22 | 吉富製薬株式会社 | アルブミン含有水溶液の精製法 |
JP2949846B2 (ja) | 1990-11-30 | 1999-09-20 | 吉富製薬株式会社 | アルブミン製剤の保存方法 |
FR2672604B1 (fr) * | 1991-02-07 | 1995-05-05 | Pasteur Merieux Serums Vacc | Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue. |
US5284777A (en) * | 1991-03-04 | 1994-02-08 | Isolab, Inc. | Combined glycated hemoglobin and immunoturbidometric glycated albumin assay from whole blood lysate |
JPH0671432B2 (ja) | 1991-03-20 | 1994-09-14 | 株式会社ミドリ十字 | ヒト血清アルブミンの製造方法 |
US5330901A (en) * | 1991-04-26 | 1994-07-19 | Research Corporation Technologies, Inc. | Expression of human serum albumin in Pichia pastoris |
DK0524681T3 (da) | 1991-07-12 | 2000-04-10 | Dsm Nv | Fremgangsmåde til oprensning af serumalbumin |
US5260308A (en) * | 1991-11-06 | 1993-11-09 | Mayo Foundation For Medical Education And Research | Method to increase permeability of the blood-nerve/brain barriers to proteins |
FR2686620B1 (fr) * | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | Serum-albumine humaine, preparation et utilisation. |
US5281582A (en) | 1992-02-27 | 1994-01-25 | Alliance Pharmaceuticals, Corp. | Serum growth factor |
US5440018A (en) | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
JPH07102148B2 (ja) * | 1992-05-20 | 1995-11-08 | 株式会社ミドリ十字 | 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物 |
JP3207201B2 (ja) * | 1992-06-24 | 2001-09-10 | ノートトライ リミテッド | 二重サイクロン式真空掃除機 |
JP3360315B2 (ja) | 1992-07-31 | 2002-12-24 | 三菱ウェルファーマ株式会社 | ヒト血清アルブミンの高度精製方法 |
CA2140331C (en) | 1992-08-03 | 2000-01-18 | John J. Carrino | Detecting and amplifying target nucleic acids using exonucleolytic activity |
DE4226971C2 (de) | 1992-08-14 | 1997-01-16 | Widmar Prof Dr Tanner | Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte |
US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
CA2116385A1 (en) | 1993-02-25 | 1994-08-26 | Akinori Sumi | Human serum albumin and process for producing the same |
DE4308532A1 (de) | 1993-03-17 | 1994-09-22 | Boehringer Mannheim Gmbh | Monoklonale Antikörper gegen in vivo glykiertes Albumin |
SE9301583D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Yeast strain and methods for expressing heterologous proteins in yeast |
CA2136564C (en) | 1993-11-26 | 2008-04-08 | Kaoru Kobayashi | Process for producing human serum albumin |
GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
JPH07308199A (ja) | 1994-05-18 | 1995-11-28 | Green Cross Corp:The | ヒト血清アルブミンの製造方法 |
JP3702474B2 (ja) | 1994-06-01 | 2005-10-05 | 三菱ウェルファーマ株式会社 | 血清アルブミン製剤の製造方法 |
GB9411356D0 (en) | 1994-06-07 | 1994-07-27 | Delta Biotechnology Ltd | Yeast strains |
WO1996003751A1 (en) * | 1994-07-21 | 1996-02-08 | Gregory Lowell Millspaugh | Method of and system for controlling energy, including in fusion reactors |
US5561115A (en) | 1994-08-10 | 1996-10-01 | Bayer Corporation | Low temperature albumin fractionation using sodium caprylate as a partitioning agent |
EP0699687B1 (en) | 1994-08-31 | 2004-01-28 | Mitsubishi Pharma Corporation | Process for purifying recombinant human serum albumin |
DE4432689A1 (de) | 1994-09-14 | 1996-03-21 | Basf Ag | Mischung aus Alkylierungsprodukten von acetalisierten Monosacchariden mit Epoxiden |
US6068995A (en) * | 1994-10-25 | 2000-05-30 | Yoshitomi Pharmaceutical Industries, Ltd. | Method for producing protein |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
WO1997031947A1 (en) * | 1996-02-29 | 1997-09-04 | Delta Biotechnology Limited | High purity albumin production process |
GB9721892D0 (en) | 1997-10-15 | 1997-12-17 | British Tech Group | Apparatus for and method of testing a sample |
GB9902000D0 (en) * | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
JP4798832B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
US6693173B2 (en) | 2000-12-26 | 2004-02-17 | Alpha Therapeutic Corporation | Method to remove citrate and aluminum from proteins |
SE0201680L (sv) | 2002-06-04 | 2003-09-02 | Wexioedisk Ab | Diskmaskin med uppsamlingsorgan för att ta emot diskvätska och sköljvätska |
-
1999
- 1999-01-30 GB GB9902000A patent/GB9902000D0/en not_active Ceased
-
2000
- 2000-01-31 MX MXPA01007719A patent/MXPA01007719A/es active IP Right Grant
- 2000-01-31 EP EP20100075421 patent/EP2272961A1/en not_active Withdrawn
- 2000-01-31 CN CNA2006101006640A patent/CN1974599A/zh active Pending
- 2000-01-31 EP EP20080166355 patent/EP2048234B1/en not_active Expired - Lifetime
- 2000-01-31 SG SG2007061591A patent/SG174629A1/en unknown
- 2000-01-31 DE DE60040967T patent/DE60040967D1/de not_active Expired - Lifetime
- 2000-01-31 JP JP2000596028A patent/JP4586150B2/ja not_active Expired - Lifetime
- 2000-01-31 CN CN2005101086585A patent/CN1810834B/zh not_active Expired - Lifetime
- 2000-01-31 CA CA2359705A patent/CA2359705C/en not_active Expired - Lifetime
- 2000-01-31 AT AT00901252T patent/ATE416254T1/de not_active IP Right Cessation
- 2000-01-31 KR KR1020057009776A patent/KR100886554B1/ko active IP Right Grant
- 2000-01-31 AU AU21207/00A patent/AU763899B2/en not_active Expired
- 2000-01-31 ES ES00901252T patent/ES2317827T3/es not_active Expired - Lifetime
- 2000-01-31 WO PCT/GB2000/000257 patent/WO2000044772A2/en active IP Right Grant
- 2000-01-31 CN CNB008032920A patent/CN1211485C/zh not_active Expired - Lifetime
- 2000-01-31 SG SG200304297A patent/SG119194A1/en unknown
- 2000-01-31 EP EP00901252A patent/EP1149163B1/en not_active Expired - Lifetime
- 2000-01-31 CN CN2004100050153A patent/CN1526732B/zh not_active Expired - Lifetime
- 2000-01-31 DK DK08166355T patent/DK2048234T3/da active
- 2000-01-31 KR KR1020017009551A patent/KR100577493B1/ko active IP Right Grant
-
2002
- 2002-06-04 HK HK07101272A patent/HK1096691A1/xx not_active IP Right Cessation
- 2002-06-04 HK HK02104220.2A patent/HK1042521B/zh unknown
-
2003
- 2003-09-23 AU AU2003248302A patent/AU2003248302B2/en not_active Expired
-
2008
- 2008-09-09 US US12/207,325 patent/US7993877B2/en not_active Expired - Fee Related
-
2010
- 2010-05-27 JP JP2010121914A patent/JP5474661B2/ja not_active Expired - Lifetime
-
2011
- 2011-07-01 US US13/175,155 patent/US9029102B2/en not_active Expired - Fee Related
-
2013
- 2013-01-15 JP JP2013004867A patent/JP5774612B2/ja not_active Expired - Lifetime
-
2014
- 2014-07-14 US US14/330,703 patent/US9555344B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2317827T3 (es) | Metodo cronomatografico de purificacion de albumina. | |
ES2219257T3 (es) | Albumina de elevada pureza producida por un procedimiento que comprende varias etapas. | |
JPH11509525A (ja) | 高純度アルブミンの製造方法 | |
KR20040111351A (ko) | 단백질 제제의 안정화 | |
US20170335310A1 (en) | Recombinant factor h and variants and conjugates thereof | |
AU2007200939B2 (en) | Process | |
ES2122951T3 (es) | Cromatografia de heparina para eritropoyetinas. |